Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference
October 10, 2018
Posters to focus on the anti-fibrotic effect of lanifibranor and the alteration of the PPAR pathway in a mouse model of systemic sclerosis (SSc)
Daix (France), October 10, 2018 – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that two abstracts on the anti-fibrotic effect of lanifibranor and the alteration of the PPARpathway in a mouse model of systemic scleorderma will be presented at the upcoming American College of Rheumatology (ACR) conference being held on October 19-24, 2018 in Chicago, Ilinois. These two posters were prepared as part of the development of lanifibranor as a treatment for SSc, for which the results of the Phase IIb study FASST (For a Systemic Sclerosis Treatment) are expected in early 2019.
The first abstract, entitled “In vivo assessment of lung fibrosis’ prevention using the pan-PPAR agonist lanifibranor in the TβRIIΔk-fib (Transgenic Mouse Model of Scleroderma) mouse model of systemic sclerosis”, shows the impact of Inventiva’s lanifibranor in the treatment of lung fibrosis in a mouse model of SSc. In this model, where transgenic (TG) mice display severe and persistent fibrosis compared to wildtype (WT), lanifibranor produced a significant protection from lung fibrosis compared to controls, reinforcing the rationale for lanifibranor trials in SSc, especially for patients showing lung fibrosis.
The second abstract, entitled “Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells;”, examines the evidence of PPAR pathway perturbations in whole tissue or explanted cells from adult or neonatal TβRIIΔk-fib;TG mice compared to WT littermates. Results suggests that the PPARpathway is downregulated in TG mice.
Pierre Broqua, Chief Scientific Officer and Co-Founder of Inventiva, commented “The data to be presented at the ACR reinforces our confidence in the potential of our lead product lanifibranor, with which we aim to address important unmet medical needs in the treatment of NASH and SSc;. We are currently evaluating lanifibranor in two parallel Phase IIb clinical studies in NASH and SSc and look forward to presenting top-line results from the SSc trial in early 2019;.”
The event details for the presentations are as follows:
Poster Titles: “In vivo assessment of lung fibrosis’ prevention using the pan-PPAR agonist lanifibranor in the TβRIIΔk-fib mouse model of systemic sclerosis”;“Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells;”
Session Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I & Poster II
Date: Sunday, October 21st and Monday, October 22nd
Time: 9:00AM- 11:00AM (CST)
Location: ACR poster sessions A and B
Lanifibranor is a next generation panPPAR modulator, designed as a moderately potent and well-balanced PPAR α, γ and δ. This unique profile was conceived in order to obtain an optimal therapeutic margin with strong efficacy and tolerance. Lanifibranor is currently being evaluated in two parallel Phase IIb clinical studies in NASH and SSc as well as in a Phase II trial in diabetic patients with NAFLD (non-alcoholic fatty liver disease).
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.